Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 08 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-0.25 Insider Own49.37% Shs Outstand227.31M Perf Week-9.84%
Market Cap110.94M Forward P/E- EPS next Y-0.16 Insider Trans0.00% Shs Float131.75M Perf Month-14.74%
Income-60.34M PEG- EPS next Q-0.06 Inst Own10.59% Short Float / Ratio15.59% / 2.64 Perf Quarter101.56%
Sales0.00M P/S- EPS this Y22.58% Inst Trans-2.76% Short Interest20.54M Perf Half Y-75.36%
Book/sh-0.02 P/B- EPS next Y33.33% ROA-145.33% Target Price3.92 Perf Year-57.79%
Cash/sh0.13 P/C3.29 EPS next 5Y- ROE-827.71% 52W Range0.20 - 2.03 Perf YTD-60.53%
Dividend- P/FCF- EPS past 5Y53.55% ROI- 52W High-79.00% Beta0.27
Dividend %- Quick Ratio0.86 Sales past 5Y15.96% Gross Margin- 52W Low112.94% ATR0.04
Employees17 Current Ratio0.86 Sales Q/Q- Oper. Margin0.00% RSI (14)45.71 Volatility7.08% 7.71%
OptionableNo Debt/Eq- EPS Q/Q-1.13% Profit Margin- Rel Volume0.11 Prev Close0.44
ShortableYes LT Debt/Eq- EarningsAug 14 BMO Payout- Avg Volume7.77M Price0.43
Recom2.50 SMA20-5.00% SMA502.32% SMA200-58.05% Volume889,442 Change-3.60%
Date Action Analyst Rating Change Price Target Change
Aug-31-23Downgrade H.C. Wainwright Buy → Neutral $5 → $1
Aug-31-23Downgrade Chardan Capital Markets Buy → Neutral
Aug-30-23Downgrade Guggenheim Buy → Neutral
Aug-30-23Downgrade CapitalOne Overweight → Equal Weight
Aug-30-23Downgrade Cantor Fitzgerald Overweight → Neutral $4.50 → $1
Aug-30-23Downgrade BTIG Research Buy → Neutral
Jul-13-23Initiated CapitalOne Overweight $5
Apr-03-23Initiated Guggenheim Buy $5
Feb-06-23Initiated Cantor Fitzgerald Overweight $4
Oct-31-22Initiated BTIG Research Buy $7
Dec-06-23 08:05AM
Nov-27-23 08:05AM
Nov-15-23 02:04PM
Nov-14-23 08:05AM
08:52AM Loading…
Nov-09-23 08:52AM
Nov-02-23 08:05AM
Nov-01-23 08:05AM
Oct-17-23 05:22PM
Oct-11-23 05:49PM
Sep-29-23 08:05AM
Sep-21-23 08:05AM
Sep-05-23 08:05AM
Aug-31-23 10:15AM
Aug-30-23 06:11AM
06:00AM Loading…
Aug-28-23 11:47AM
Aug-14-23 09:55AM
Aug-01-23 08:45AM
Jun-11-23 08:45AM
Jun-06-23 01:59PM
May-15-23 08:05AM
Apr-27-23 08:05AM
Apr-10-23 11:43AM
Mar-13-23 07:00AM
Feb-14-23 08:05AM
Feb-07-23 08:05AM
Jan-19-23 08:05AM
Jan-11-23 01:00PM
08:05AM Loading…
Jan-09-23 08:05AM
Jan-02-23 07:31AM
Dec-29-22 09:05AM
Dec-23-22 09:00AM
Dec-22-22 08:05AM
Dec-01-22 08:05AM
Nov-22-22 08:05AM
Nov-01-22 09:55AM
Oct-28-22 08:05AM
Oct-05-22 06:09AM
Sep-27-22 08:05AM
Sep-26-22 08:35AM
Sep-07-22 08:05AM
Aug-30-22 09:39AM
Aug-15-22 08:05AM
Aug-10-22 08:05AM
Aug-04-22 08:05AM
Jul-26-22 07:18AM
Jul-05-22 08:05AM
Jun-14-22 08:05AM
May-31-22 08:05AM
May-27-22 07:25AM
May-18-22 08:05AM
May-13-22 08:05AM
May-10-22 08:35AM
May-09-22 08:35AM
May-04-22 12:02PM
Apr-22-22 08:05AM
Apr-05-22 08:05AM
Apr-04-22 07:45PM
Mar-31-22 08:05AM
Mar-03-22 08:05AM
Feb-24-22 08:05AM
Feb-16-22 10:59AM
Feb-14-22 08:05AM
Feb-10-22 08:05AM
Feb-08-22 08:05AM
Feb-02-22 05:38PM
Jan-25-22 08:05AM
Jan-19-22 08:05AM
Jan-12-22 10:35AM
Jan-04-22 08:35AM
Dec-22-21 08:05AM
Dec-15-21 08:05AM
Dec-09-21 08:05AM
Nov-29-21 04:15PM
Nov-24-21 06:49AM
Nov-23-21 10:30PM
Nov-13-21 11:00AM
Nov-10-21 08:05AM
Nov-04-21 02:30PM
Nov-03-21 08:05AM
Oct-15-21 08:41AM
Oct-12-21 12:00PM
Oct-07-21 08:05AM
Oct-05-21 08:05AM
Sep-28-21 08:05AM
Sep-21-21 08:05AM
Sep-13-21 08:05AM
Sep-08-21 08:05AM
Aug-26-21 09:57AM
Aug-13-21 08:05AM
Aug-11-21 08:05AM
Aug-03-21 05:34PM
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dagnon TerryChief Operations OfficerApr 20Sale1.14520,000590,200653,058Apr 21 09:05 PM
Evanson JeffChief Commercial OfficerJan 20Sale1.11267,000296,370745,975Jan 24 08:08 PM
Evanson JeffChief Commercial OfficerJan 19Sale1.22103,255125,9711,012,975Jan 19 08:05 PM
Evanson JeffChief Commercial OfficerJan 18Sale1.2533,73842,1721,116,230Jan 19 08:05 PM
Evanson JeffChief Commercial OfficerJan 17Sale1.3127,16235,5821,149,968Jan 19 08:05 PM